EUVIMEDEUVIMED entdecken
Crossref

Hepatic Hypertrophy in Normal and Cirrhotic Livers Following Portal Vein Embolization: Comparative Assessment of 2 Different Embolic Regimens in a Large Animal Model

Tom N Kuhn, Vinzent H Kahl, Yifan Wang, Antonia M Berz, Annabella Shewarega, Jessica G Santana, Gerald Antoch, Julius Chapiro, Todd Schlachter, David C Madoff

Journal of Vascular and Interventional Radiology · 2023

DOI: 10.1016/j.jvir.2023.08.024 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Vascular and Interventional Radiology, 2023. Verfasst von Tom N Kuhn und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, Connecticut; Department of Diagnostic and Interventional Radiolog…. Hauptthemen laut MEDLINE: Embolization, Therapeutic, Liver Neoplasms, Embolism. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: To compare the mechanistic effects and hypertrophy outcomes using 2 different portal vein embolization (PVE) regimens in normal and cirrhotic livers in a large animal model. METHODS AND MATERIALS: The Institutional Animal Care and Use Committee approved all experiments conducted in this study. Fourteen female Yorkshire pigs were separated into a cirrhotic group (CG, n = 7) and non-cirrhotic group (NCG, n = 7) and further subgrouped into those using microspheres and coils (MC, n = 3) or n-butyl cyanoacrylate (nBCA, n = 3) and their corresponding controls (each n = 1). A 3:1 ethiodized oil and ethanol mixture was administered intra-arterially in the CG to induce cirrhosis 4 weeks before PVE. Animals underwent baseline computed tomography (CT), PVE including pre-PVE and post-PVE pressure measurements, and CT imaging at 2 and 4 weeks after PVE. Immunofluorescence stainings for CD3, CD16, Ki-67, and caspase 3 were performed to assess immune cell infiltration, hepatocyte proliferation, and apoptosis. Statistical significance was tested using the Student's t test. RESULTS: Four weeks after PVE, the percentage of future liver remnant (FLR%) increased by 18.8% (standard deviation [SD], 3.6%) vs 10.9% (SD, 0.95%; P < .01) in the NCG vs CG. The baseline percentage of standardized future liver remnant (sFLR%) for the controls were 41.6% for CG vs 43.6% for NCG. Based on the embolic agents used, the sFLR% two weeks after PVE was 58.4% (SD, 3.7%) and 52.2% (SD, 0.9%) (P < .01) for MC and 46.0% (SD, 2.2%) and 47.2% (SD, 0.4%) for nBCA in the NCG and CG, respectively. Meanwhile, the sFLR% 4 weeks after PVE was 60.5% (SD, 3.9%) and 54.9% (SD, 0.8%) (P < .01) and 60.4% (SD, 3.5%) and 54.2% (SD, 0.95%) (P < .01), respectively. Ki-67 signal intensity increased in the embolized lobe in both CG and NCG (P < .01). CONCLUSIONS: This preclinical study demonstrated that MC could be the preferred embolic of choice compared to nBCA when a substantial and rapid FLR increase is needed for resection, in both cirrhotic and non-cirrhotic livers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Embolization, TherapeuticLiver NeoplasmsEmbolismAnimalsFemaleSwinePortal VeinKi-67 AntigenLiverHepatectomyHypertrophyLiver CirrhosisModels, AnimalTreatment Outcome

Substanzen

Ki-67 Antigen

Autor:innen und Institutionen

  • Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, Connecticut; Department of Diagnostic and Interventional Radiology, University Düsseldorf, Medical Faculty, Düsseldorf, Germany.
  • Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, Connecticut.
  • Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, Connecticut; Department of Radiology, Charité-Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin,…
  • Department of Diagnostic and Interventional Radiology, University Düsseldorf, Medical Faculty, Düsseldorf, Germany.
  • Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, Connecticut; Section of Medical Oncology, Department of Medicine, Yale School of Medicine, New Haven, Connecticut; Section of Surgical…

Förderung

  • NCI NIH HHS

Zitieren

APA

Kuhn, T. N., Kahl, V. H., Wang, Y., Berz, A. M., Shewarega, A., Santana, J. G., Antoch, G., Chapiro, J., Schlachter, T., & Madoff, D. C. (2023). Hepatic Hypertrophy in Normal and Cirrhotic Livers Following Portal Vein Embolization: Comparative Assessment of 2 Different Embolic Regimens in a Large Animal Model. Journal of Vascular and Interventional Radiology. https://doi.org/10.1016/j.jvir.2023.08.024

Vancouver

Kuhn TN, Kahl VH, Wang Y, Berz AM, Shewarega A, Santana JG, et al. Hepatic Hypertrophy in Normal and Cirrhotic Livers Following Portal Vein Embolization: Comparative Assessment of 2 Different Embolic Regimens in a Large Animal Model. Journal of Vascular and Interventional Radiology. 2023. doi:10.1016/j.jvir.2023.08.024

BibTeX
@article{Kuhn2023,
  author = {Kuhn, Tom N and Kahl, Vinzent H and Wang, Yifan and Berz, Antonia M and Shewarega, Annabella and Santana, Jessica G and Antoch, Gerald and Chapiro, Julius and Schlachter, Todd and Madoff, David C},
  title = {Hepatic Hypertrophy in Normal and Cirrhotic Livers Following Portal Vein Embolization: Comparative Assessment of 2 Different Embolic Regimens in a Large Animal Model},
  journal = {Journal of Vascular and Interventional Radiology},
  year = {2023},
  doi = {10.1016/j.jvir.2023.08.024}
}
Kostenlos starten →